Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk reports significant weight loss in children as young as six using Wegovy, though trial cancellations have pressured company stock.
10 trends tracked about this subject — the full history, oldest to newest below.
Novo Nordisk reports significant weight loss in children as young as six using Wegovy, though trial cancellations have pressured company stock.
Recent coverage examines findings that the GLP-1 drug semaglutide extends lifespan and slows ageing in older female mice.
Recent studies reveal that the GLP-1 receptor agonist semaglutide extends lifespan and slows physiological aging in animal models.
Emerging research suggests GLP-1 medications, primarily known for weight loss, may offer an unexpected therapeutic benefit in treating substance addictions.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
Researchers screening 6,000 existing medications have identified potential anti-aging properties in common drugs, including GLP-1 weight loss treatments.
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
New research indicates that GLP-1 obesity medications may provide unexpected benefits for male fertility by increasing testosterone and sperm quality.
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss